


Rec'd 1/17



U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

**REQUEST FOR CORRECTED FILING
RECEIPT**

Docket Number:
2664/60804 (formerly 12670/60804)

Application Number
10/626,036

Filing Date
July 23, 2003

Examiner
Not Yet Assigned

Art Unit
1625

Invention Title
**PREPARATION OF 1H-IMIDAZO [4,5-C]
QUINOLIN-4-AMINES VIA 1H-IMIDAZO [4,5-C]
QUINOLIN-4-PHTHALIMIDE INTERMEDIATES**

Inventor(s)
V. Merli, et al.

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on

Date: 6 May 04 Reg. No. 29770

Signature: Pietro T. J. Bucce

Sir:

Applicants respectfully request that the filing receipt be corrected to show the name of the third inventor as follows:

- -Stefano BIANCHI- -

The correct name of the inventor is shown in the Declaration mailed to the Patent Office on November 13, 2003.

Applicants respectfully request that the Attorney Docket Number for this application be changed as follows:

- -2664/60804 --

A copy of the Filing Receipt with the changes shown in red is also enclosed.

Please issue a corrected filing receipt as requested above.

If any fees are due, the Commissioner is authorized to charge them to Kenyon & Kenyon
Deposit Account No. 11-0600.

Dated: 6 May 04

By:



Patrick J. Birde
(Reg. No. 29,770)

KENYON & KENYON
One Broadway
New York, New York 10004-1050
(212) 425-7200 (Telephone)
(212) 425-5288 (Facsimile)

CUSTOMER NUMBER 26646



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPL NO.	FILING OR 371 (c) DATE	ART UNIT	FIL FEE REC'D	ATTY.DOCKET NO	DRAWINGS	TOT CLMS	IND CLMS
10/626,036	07/23/2003	1625	1544	42670/60804 2004/60804		21	5

26646
KENYON & KENYON
ONE BROADWAY
NEW YORK, NY 10004

CONFIRMATION NO. 1257

UPDATED FILING RECEIPT



OC000000012314142

Date Mailed: 04/09/2004

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Valeriano Merli, Cremella Lecco, ITALY;
Silvia Mantovani, Lendinara, ITALY;
Bianchi-Stefano, Breccia Como, ITALY;
STEFANO BIANCHI

Domestic Priority data as claimed by applicant

This appln claims benefit of 60/397,607 07/23/2002

Foreign Applications

If Required, Foreign Filing License Granted: 12/04/2003

Projected Publication Date: 07/15/2004

Non-Publication Request: No

Early Publication Request: No

Title

Preparation of 1H-imidazo [4,5-C] quinolin-4-amines via 1H-imidazo [4,5-C] quinolin -4-phthalimide intermediates

Preliminary Class

546

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related application(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).